Although APEX1 has been reported diagnosis value of ccRCC, its clinical practical prospective was still a long way.40 In recent years, the potential of snoRNA as biomarkers has been graduated recognized.15, 16, 41 For example, SNORA42 was identified as a novel diagnostic, predictive biomarker and prospective therapeutic targets for CRC patients.15 In our study, we identified a six‐snoRNA signature as the diagnosis marker depending on TCGA database and validated its value to distinguish ccRCC patients and healthy people in tissue and serum samples. The gene discussed is SNORA80E; the disease is nonpapillary renal cell carcinoma.